What MiLaboratories does

MiLaboratories is a privately held computational biology company building software for genomic data analysis, with a particular focus on immune repertoire profiling and next-generation sequencing (NGS) workflows. Its core commercial product, Platforma.bio, is a software development kit designed to enable biologists to perform genomic analyses independently, removing the traditional dependency on specialized bioinformaticians and compressing time-to-insight for drug discovery and biomedical research teams. The company complements Platforma.bio with VDJ.online, a web-accessible VDJ analysis tool, and MiXCR, an established open-source tool for immune repertoire sequencing that anchors an active GitHub developer community and serves as a top-of-funnel ecosystem asset. The technology stack targets both independent researchers and enterprise pharmaceutical R&D, with publicly disclosed customers including Moderna and Bristol Myers Squibb.

The company is headquartered in San Francisco, California (MiLaboratories Inc., 2261 Market St #5094) and operates an R&D facility in Bilbao, Spain, reflecting a transatlantic operating model with European technical roots and US commercial orientation. MiLaboratories has raised approximately $12.36 million across two disclosed rounds — a ~$2.36M early-stage round in February 2022 led by Acrobator Ventures and Speedinvest, and a $10 million Series A in October 2024 led by Madrid-based K Fund with participation from Speedinvest, Acrobator Ventures, Courtyard Ventures, EGB Capital, Somersault Ventures, and TEN13. The Series A is explicitly allocated to talent acquisition and US market expansion, with secondary investment in community development and platform feature breadth.

Commercially, MiLaboratories employs a hybrid go-to-market motion: a product-led, self-serve distribution channel through platforma.bio (with license requests routed via a getlicense portal) layered with an enterprise field sales motion targeting large pharma and biotech accounts. Revenue is generated through subscription-based licensing of the Platforma.bio SDK on an annual billing cadence, though public pricing is not disclosed. Marketing is community-led, centered on the GitHub developer ecosystem around MiXCR and active presence on LinkedIn, Twitter/X, and YouTube. The company has 11–50 employees and is led by co-founder and CEO Stanislav Poslavsky alongside co-founder/COO Alexey Nechaev, CTO/co-founder Dmitriy Bolotin, and co-founder/CSO Dmitriy Chudakov.

Name

MiLaboratories

Legal name

MiLaboratories Inc.

Website

https://milaboratories.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

MiLaboratories is a computational biology software company whose Platforma.bio SDK enables biologists to analyze next-generation sequencing and immune repertoire data without dedicated bioinformaticians, serving enterprise pharma customers such as Moderna and Bristol Myers Squibb.

Ownership category

akta.pro rank

Product category

Computational Biology Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industry

Developer Tooling & SDK Platforms (BPAMAOAD)

Keywords

• Computational biology software
• Genomic data analysis
• Immune repertoire profiling
• Bioinformatics platform
• NGS data processing

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D

Revenue model

1. Platforma.bio SDK Licenses: The company licenses its Platforma.bio software development kit to biologists and pharmaceutical researchers, providing a commercial platform for genomic data analysis. Revenue is generated through software licensing for commercial use.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

MiLaboratories develops the Platforma.bio software development kit (SDK), a computational biology platform that enables biologists to process next-generation sequencing (NGS) and genomic data independently, without relying on specialized bioinformaticians. The company also maintains open-source immune repertoire tools (MiXCR) and the VDJ.online web platform, supporting genomic research and drug discovery workflows for pharmaceutical and biomedical customers.

Product overview

MiLaboratories operates as a computational biology company offering a platform-based architecture centered around Platforma.bio, a software development kit designed to transform genomic data analysis for drug discovery and biomedical research. The company also provides VDJ.online as an additional tool for VDJ analysis. Platforma.bio serves as the core platform enabling biologists to analyze genomic data independently, reducing reliance on specialized bioinformaticians. Notable customers include major pharmaceutical companies such as Moderna and Bristol Myers Squibb.

Differentiator

Problem solved

Functional benefit

Brands

• Platforma.bio: Software development kit for simplifying and accelerating genomic data analysis for biologists, reducing dependence on bioinformaticians and promoting collaboration in genomics research.
• VDJ.online

Products and services

• Platforma.bio SDK A computational biology platform and software development kit that enables biologists and bioinformaticians to analyze next-generation sequencing and genomic data independently, without relying on dedicated bioinformatician expertise. Licensed commercially to pharmaceutical and biotech customers for drug discovery and biomedical research.
• VDJ.online An online web-accessible platform for VDJ analysis and related immune repertoire genomic data processing, offered alongside Platforma.bio for biologists performing immune repertoire research.
• MiXCR An open-source tool for immune repertoire sequencing data analysis distributed via GitHub, used by the genomics research community for clonotype and VDJ analysis.

Quantifiable outcome

• Reduces the need for dedicated bioinformaticians in genomic data analysis workflows
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Illumina (BaseSpace, DRAGEN): Illumina offers BaseSpace Sequence Hub and DRAGEN, end-to-end NGS data analysis platforms used by pharma and academic labs. Overlaps with MiLaboratories on genomic data analysis but bundles software with Illumina's dominant sequencing instruments, serving as a broad incumbent rather than a niche specialist.
• 10x Genomics: 10x Genomics provides single-cell and immune repertoire sequencing solutions (e.g., Chromium, Cell Ranger) and adjacent software. Comparable to MiLaboratories in the immune repertoire domain, but operates as a much larger incumbent with bundled wet-lab and software products.
• Dotmatics: Dotmatics provides a scientific R&D platform spanning biology, chemistry, and informatics for pharma customers. Comparable as a broader life-science informatics incumbent whose platform overlaps with MiLaboratories' pharma R&D software positioning.
• Bio-Techne: Bio-Techne is a large life-science tools company offering reagents, instruments, and software (including bioinformatics) used in pharma and academic R&D. Comparable as a broad incumbent in life-science research tools with overlapping informatics capabilities.

Direct peers

• DNAnexus: DNAnexus provides a cloud-based biomedical informatics and genomic data analysis platform used by pharma and clinical customers. Directly comparable to Platforma.bio as a SaaS bioinformatics platform serving pharmaceutical R&D with enterprise-grade data management.
• Sophia Genetics: Sophia Genetics offers a genomic and radiomic data analysis platform deployed at hospitals and biopharma customers. Comparable as a SaaS bioinformatics platform selling analysis workflows to enterprise life-science customers, though more weighted toward clinical genomics than immune repertoire.
• Partek Incorporated: Partek provides genomic data analysis software (Partek Flow, Partek Genomics Suite) for biologists and bioinformaticians. Directly comparable to Platforma.bio as a software vendor simplifying NGS analysis workflows for biomedical researchers.
• Qlucore: Qlucore develops visualization and statistical analysis software for genomics and life science data. Comparable to MiLaboratories as a smaller bioinformatics software vendor focused on simplifying complex data analysis for biology researchers.
• Velsera (formerly Seven Bridges): Velsera operates a clinical and genomics informatics platform serving pharma and clinical customers with NGS analysis workflows. Directly comparable to Platforma.bio as an enterprise bioinformatics platform for genomic data analysis in drug discovery and clinical research.

Emerging players

• Arima Genomics: Arima Genomics focuses on 3D genome and spatial genomics applications with adjacent software tools. Comparable as an emerging genomics tools company, though more specialized in structural genomics than immune repertoire analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/MiLaboratories
• GitHubgithub.com/milaboratory
• YouTubeyoutube.com/@MiLaboratories
• LinkedInlinkedin.com/company/milaboratories

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiLaboratories